Breaking News Instant updates and real-time market news.

CC

Chemours

$13.86

0.46 (3.43%)

, CE

Celanese

$118.24

-0.51 (-0.43%)

07:06
10/11/19
10/11
07:06
10/11/19
07:06

SunTrust sees 'lackluster' September quarter results from chemical companies

SunTrust analyst James Sheehan tells investors in a research note that he expects chemical companies to report in-line to below-consensus Q3 results driven by the trade war, slowing GDP in Europe, weak automotive and manufacturing end markets, loosening supply/demand for certain commodity product chains and FX headwinds. Looking ahead, the analyst sees "cautious" commentary for Q4 given the lack of end market acceleration and continued USD strength. The analyst lowered his price target for Chemours (CC) to $16 from $14, for Dow Inc (DOW) to $46 from $52, for Corteva (CTVA) to $28 from $30, for DuPont (DD) to $68 from $75, for Eastman Chemical (EMN) to $75 from $80, for Element Solutions (ESI) to $10 from $11, for Kraton (KRA) to $24 from $33 and for Kronos Worldwide (KRO) to $12 from $13. Sheehan raised his price target for Celanese (CE) to $120 from $108.

CC

Chemours

$13.86

0.46 (3.43%)

CE

Celanese

$118.24

-0.51 (-0.43%)

CTVA

Corteva

$25.72

-0.46 (-1.76%)

DD

DuPont

$63.13

-1.65 (-2.55%)

DOW

Dow Inc.

$44.90

0.88 (2.00%)

EMN

Eastman Chemical

$69.81

0.48 (0.69%)

ESI

Element Solutions

$9.33

-0.12 (-1.27%)

KRA

Kraton

$20.44

-9.62 (-32.00%)

KRO

Kronos Worldwide

$11.57

0.14 (1.22%)

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 31

    Oct

CC Chemours
$13.86

0.46 (3.43%)

09/09/19
BMOC
09/09/19
NO CHANGE
Target $23
BMOC
Outperform
Chemours price target lowered to $23 from $31 at BMO Capital
BMO Capital analyst John McNulty lowered his price target on Chemours to $23 while also cutting his FY19 EPS view to $2.31 from $2.80 to reflect the pressures in its fluoroproducts business and the "slow pace" of its return to titanium dioxide market. The analyst calls these "appropriately conservative" and keeps his Outperform rating on the stock to reflect his expectation of improved cash flows and "washed out" valuation, though he also believes that the Street consensus earnings will still need to come solidly lower.
08/20/19
SUSQ
08/20/19
UPGRADE
SUSQ
Positive
Chemours upgraded to Positive from Neutral at Susquehanna
08/20/19
08/20/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pilgrim's Pride (PPC) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow citing the management's implementation of a "successful execution" of its chicken strategy. 2. Beyond Meat (BYND) upgraded to Overweight from Neutral at JPMorgan while Campbell Soup (CPB) was upgraded to Neutral from Underweight. 3. Chemours (CC) upgraded to Positive from Neutral at Susquehanna with analyst Don Carson saying he thinks end-user destocking of TiO2 appears to have run its course and he views the company as the prime beneficiary of an upturn in industry volumes in 2020. 4. AbbVie (ABBV) upgraded to Overweight from Neutral at Piper Jaffray with analyst Christopher Raymond saying while he remains negative on the company's decision to acquire Allergan (AGN), he believes that a bottom on the stock has been found around $66. 5. CACI (CACI) upgraded to Outperform from Neutral at Credit Suisse with analyst Robert Spingarn saying in an uncertain macro environment, he likes a defensive name that can support a multi-year story of organic growth, margin expansion, and M&A optionality, all while offering an attractive valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/20/19
SUSQ
08/20/19
UPGRADE
Target $18
SUSQ
Positive
Susquehanna upgrades Chemours to Positive, cuts target to $18
As previously reported, Susquehanna upgraded Chemours to Positive from Neutral. In a note to investors prior to the open, analyst Don Carson said he thinks end-user destocking of TiO2 appears to have run its course and he views the company as the prime beneficiary of an upturn in industry volumes in 2020. He also thinks litigation worries about PFAS have been overdone, said Carson, who lowered his price target on Chemours shares to $18 from $37.
CE Celanese
$118.24

-0.51 (-0.43%)

10/01/19
10/01/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Celanese (CE) downgraded to Neutral from Buy at Goldman Sachs with analyst Robert Koort citing valuation. 2. Welltower (WELL) downgraded to Equal Weight from Overweight at Barclays with analyst Steven Valiquette citing valuation. 3. Xilinx (XLNX) downgraded to Sector Weight from Overweight at KeyBanc. 4. Public Storage (PSA) downgraded to Underperform from In Line at Evercore ISI. 5. Thor Industries (THO) downgraded to Neutral from Buy at Northcoast with analyst Brandon Rolle saying he views shares as "fairly" valued following yesterday's rally and would get more constructive if there was evidence of improving North American retail demand and market share stabilization. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/19
GSCO
10/01/19
DOWNGRADE
Target $129
GSCO
Neutral
Celanese downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Robert Koort downgraded Celanese to Neutral from Buy and lowered his price target for the shares to $129 from $130. The analyst sees a less compelling risk/reward with the shares near his price target. He cites valuation for the downgrade saying Celanese's recent outperformance diminishes the stock's upside potential.
09/26/19
BOFA
09/26/19
INITIATION
Target $110
BOFA
Underperform
Celanese initiated with an Underperform at BofA/Merrill
BofA/Merrill analyst Matthew DeYoe initiated Celanese with an Underperform and $110 price target telling the current valuation is "extended." He believes management's outlook gives little room for error and thinks investors are underestimating the risks back to profitability given the macro backdrop that could decelerate further.
10/08/19
DBAB
10/08/19
NO CHANGE
DBAB
Hold
Celanese breakup largely priced into shares, says Deutsche Bank
Deutsche Bank analyst David Begleiter says Bloomberg's report last night that Celanese is undergoing a strategic review that could include a breakup of the company is not a complete surprise. Celanese management has been quite open over the past 18 months on their desire to do a tax-efficient transaction with its Engineered Materials business and DuPont's Transportation & Industrial segment, Begleiter tells investors in a research note. As a result, the analyst believes a breakup is largely priced in at current share levels. He keeps a Hold rating on Celanese.
CTVA Corteva
$25.72

-0.46 (-1.76%)

08/09/19
RBCM
08/09/19
UPGRADE
Target $38
RBCM
Outperform
Corteva upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital analyst Arun Viswanathan upgraded Corteva to Outperform and raised his price target to $38 from $29 after its Q2 earnings beat. The analyst says that after a year of negative weather in 2019 due to delayed corn and soybean plantings, the impact for ag companies could turn positive in 2020. The analyst also believes that Corteva could generate $2.3B-$2.35B in 2020 EBITDA from deal synergies and "modest" new product growth.
08/09/19
RBCM
08/09/19
UPGRADE
RBCM
Outperform
Corteva upgraded to Outperform from Sector Perform at RBC Capital
08/19/19
SBSH
08/19/19
UPGRADE
Target $34.5
SBSH
Buy
Citi upgrades Corteva to Buy after tough 2019, says 2020 should be better
As previously reported, Citi analyst P.J. Juvekar upgraded Corteva to Buy from Neutral, stating that he sees a positive path forward going into 2020 after the company "was hit with a confluence of negative factors" in 2019. In the coming year, Corteva has several products in the pipeline, should see strong growth outside the U.S. and can benefit from multiple productivity programs as a new company on top of merger-related synergies, Juvekar tells investors. He edged his price target on Corteva shares up to $34.50 from $34 on higher expected earnings.
08/19/19
SBSH
08/19/19
UPGRADE
SBSH
Buy
Corteva upgraded to Buy from Neutral at Citi
DD DuPont
$63.13

-1.65 (-2.55%)

09/10/19
09/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DuPont (DD) initiated with a Buy at Jefferies. 2. Turning Point Therapeutics (TPTX) initiated with an Outperform at Wedbush. 3. Aurinia Pharmaceuticals (AUPH) initiated with an Outperform at Oppenheimer. 4. Banco de Chile (BCH) initiated with a Neutral at Goldman Sachs. 5. McEwen Mining (MUX) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/19
JEFF
09/10/19
INITIATION
Target $85
JEFF
Buy
DuPont initiated with a Buy at Jefferies
Jefferies analyst Laurence Alexander started DuPont with a Buy rating and $85 price target. Better operating discipline and a commitment to "exploit its freedom to maneuver" should make DuPont shares more resilient against a soft macroeconomic backdrop, Alexander tells investors in a research note. He believes the current productivity cycle and DuPont's "robust" free cash flow could drive 4.1% annual sales growth and 12% annual earnings growth through the middle of the next decade.
09/10/19
SBSH
09/10/19
NO CHANGE
SBSH
Buy
DuPont management 'seems relentless' in driving value, shares Citi
After meeting with DuPont, Citi analyst P.J. Juvekar believes management "seems relentless" in driving shareholder value through portfolio trades. He reiterates a Buy rating on the shares with a sum-of-the-parts price target of $82. DuPont offers a "clear story for value realization" through portfolio moves, Juvekar tells investors in a research note.
09/04/19
MSCO
09/04/19
NO CHANGE
Target $85
MSCO
Overweight
Morgan Stanley says new round of chemical industry consolidation may be coming
Morgan Stanley analyst Vincent Andrews notes that DuPont (DD) can pursue further tax-free strategic options as of September 1, which was the two-year anniversary of the DowDuPont merger, and he also notes that DuPont and Celanese (CE) executives have made public comments about strategic alternatives being a clear priority. Andrews, who thinks "converging forces" may create the environment for a new round of chemical industry consolidation and other dealmaking, believes Celanese, DuPont and DSM (RDSMY) could "be the nexus of any activity" given their size, resources and management commentary. Citing his view that the market will increasingly price in potential M&A, Andrews increased his price target on DuPont shares to $85 from $78, raised his Celanese target to $124 from $102 and upped his DSM target to EUR104 from EUR90. He recommends DuPont as the best way to play the chemical consolidation theme and keeps an Overweight rating on the shares, while keeping Equal Weight ratings on the other two stocks named above.
DOW Dow Inc.
$44.90

0.88 (2.00%)

08/16/19
BOFA
08/16/19
NO CHANGE
BOFA
BofA/Merrill shakes up ratings in chemicals space with 2 upgrades, 4 downgrades
BofA Merrill Lynch analyst Steve Byrne said it appears that risks of U.S. economic contagion from the broader global macro slowdown are "steadily building." Given this view, he has generally moved to be more cautious on the earnings outlook and ratings for stocks with global industrial exposure, resulting in his upgrade of two chemicals stocks and his downgrades of four others. Byrne downgraded Dow Inc. (DOW) to Underperform from Neutral and Westlake Chemical (WLK) to Underperform from Buy, noting their commodity exposure. He downgraded Axalta Coating (AXTA) to Neutral from Buy and cut PPG (PPG) to Underperform from Neutral as he is getting more cautious about their revenue prospects. He upgraded Venator Materials (VNTR) to Buy from Underperform, citing what he views as an attractive risk-reward as he expects earnings will grow in 2020, driven by product upgrades and productivity initiatives. Byrne also upgraded Nutrien (NTR) to Neutral from Underperform as he believes Ag stocks could prove to be defensive plays.
08/16/19
BOFA
08/16/19
DOWNGRADE
BOFA
Underperform
Dow Inc. downgraded to Underperform from Neutral at BofA/Merrill
07/31/19
07/31/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Hold from Buy at Craig-Hallum with analyst Christian Schwab citing the company's earnings and "disappointing" guidance for the third quarter that missed both his and Street expectations due to lower than anticipated Semicustom revenue expectations. 2. Dow Inc. (DOW) downgraded to Outperform from Top Pick at RBC Capital with analyst Arun Viswanathan citing the "compression in the PU/siloxanes earnings" as well as softer macro conditions. 3. Total (TOT) downgraded to Equal Weight from Overweight at Morgan Stanley. 4. Broadridge (BR) downgraded to Market Perform from Outperform at Raymond James with analyst Patrick O'Shaughnessy saying the risk/reward is balanced at current share levels. 5. T2 Biosystems (TTOO) downgraded to Neutral from Overweight at Cantor Fitzgerald and to Neutral from Buy at Janney Montgomery Scott and H.C. Wainwright. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/19
RBCM
07/31/19
DOWNGRADE
Target $56
RBCM
Outperform
Dow Inc. downgraded to Outperform from Top Pick at RBC Capital
RBC Capital analyst Arun Viswanathan downgraded Dow to Outperform and lowered his price target to $56 from $62, citing the "compression in the PU/siloxanes earnings" as well as softer macro conditions. The analyst adds that the company still offers "industry-leading capital return" and organic growth, with 6.2-times his expected 2020 EBITDA multiple seen as "good value".
EMN Eastman Chemical
$69.81

0.48 (0.69%)

09/26/19
BOFA
09/26/19
INITIATION
Target $84
BOFA
Buy
Eastman Chemical initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Matthew DeYoe initiated Eastman Chemical with a Buy and $84 price target saying current valuation does not reflect strength in consistent cash flow generation. The analyst notes debt repayments are becoming less, which should allow cash to be returned to shareholders, and sees several levers to defend growth in a soft market. Further, significant expansion of operations throughout 2018 provides room for growth and mix improvement with little incremental spend.
07/29/19
JPMS
07/29/19
DOWNGRADE
Target $80
JPMS
Neutral
Eastman Chemical downgraded to Neutral on contracting volumes at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Eastman Chemical to Neutral from Overweight and lowered his price target for the shares to $80 from $88. The analyst says his EBITDA estimates for 2019 and 2020 are below previous forecasts due to contracting volumes and prices across Eastman's business portfolio. The company's earnings are sensitive to relatively modest changes in a handful of large volume, commodity raw materials petrochemicals, including propane, propylene, ethane, and ethylene, Zekauskas tells investors in a research note.
07/29/19
JPMS
07/29/19
DOWNGRADE
Target $80
JPMS
Neutral
Eastman Chemical downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Eastman Chemical to Neutral from Overweight and lowered his price target for the shares to $80 from $88.
08/15/19
TUDR
08/15/19
UPGRADE
TUDR
Buy
Eastman Chemical upgraded to Buy from Hold at Tudor Pickering
ESI Element Solutions
$9.33

-0.12 (-1.27%)

KRA Kraton
$20.44

-9.62 (-32.00%)

10/26/18
10/26/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Colgate-Palmolive (CL) downgraded to Hold from Buy at SunTrust with analyst William Chappell citing "another disappointing" quarterly result this morning. 2. Cerner (CERN) downgraded to Sector Perform from Outperform at RBC Capital with analyst George Hill saying the slowing market for health care information technology companies, as well as the company's slower rate of growth, warrant a lower multiple on the stock. 3. Kraton (KRA) downgraded to Hold from Buy at SunTrust with analyst James Sheehan saying the management has cited "weakening demand, tariff impacts, escalating logistics costs and an extended plant outage" in reducing its outlook. 4. Western Digital (WDC) downgraded to Neutral from Buy at Longbow, to Neutral from Overweight at JPMorgan, as well as to Hold from Buy at Benchmark and Craig-Hallum. 5. Jack in the Box (JACK) downgraded to Neutral from Outperform at Wedbush with analyst Nick Setyan saying given the company's franchised model and franchisee unrest, he can no longer assume that many of the initiatives through FY22 that his positive recommendation was based on will occur. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/10/18
STFL
12/10/18
INITIATION
Target $22
STFL
Hold
Kraton initiated with a Hold at Stifel
Stifel analyst Vincent Anderson initiated Kraton with a Hold rating and a price target of $22. The analyst notes that the company has exposure to "good longer term growth outlets" in medical and personal care but also faces near term headwinds from "competitively priced substitutes in SBCs, rubber, and pine chemicals". Anderson also points to the recent plant outage delaying Kraton's deleveraging.
01/24/19
LOOP
01/24/19
NO CHANGE
Target $59
LOOP
Buy
Kraton shares 'unjustifiably' cheap, says Loop Capital
Loop Capital analyst Chris Kapsch kept his Buy rating and $59 price target on Kraton, saying his recent conversations with its CFO Chris Russell did not indicate any "trepidation about recent macroeconomic and/or trade developments tied to China." While Russell acknowledged some of the operational "hiccups" in Q3, Kapsch notes that much of the distraction was related to Kraton's operations in the Florida panhandle, where one of the company's CTO refineries operates. The analyst adds that Kraton shares are "very cheap" given the company's "relatively-differentiated portfolio mix, attractive end-market profile, and healthy EBITDA margins", but he is uncertain of what catalyst can shift investor perception toward greater value for the stock.
03/01/19
RHCO
03/01/19
NO CHANGE
Target $39
RHCO
Buy
Kraton price target raised to $39 from $27 at SunTrust
SunTrust analyst James Sheehan raised his price target on Kraton to $39 amid the rising peer group valuations and to reflect the possibility of value creation from the potential divestiture of its "highly profitable ariflexisoprene rubber business". The analyst also keeps his Hold rating on the shares because its progress on deleveraging is being "stalled by macro headwinds and costs from unplanned outages", noting that Kraton stock will likely trade range bound.
KRO Kronos Worldwide
$11.57

0.14 (1.22%)

11/23/18
DBAB
11/23/18
NO CHANGE
Target $15
DBAB
Buy
Deutsche cuts Kronos target to $15 but sees attractive valuation here
Deutsche Bank analyst David Begleiter lowered his price target for Kronos Worldwide to $15 from $26 but keeps a Buy rating on the shares. After declining 50%, the stock fully reflects falling European TiO2 prices and broader concerns over the TiO2 cycle, Begleiter tells investors in a research note. European TiO2 prices fell 4% in Q4 and are likely to fall further in Q1 amid soft demand, destocking and increased Chinese exports, says the analyst. However, Begleiter continues to believe industry fundamentals are supportive of an elongated TiO2 cycle. He views Kronos Worldwide's valuation as attractive at current share levels.

TODAY'S FREE FLY STORIES

BX

Blackstone

$47.10

0.62 (1.33%)

16:34
10/13/19
10/13
16:34
10/13/19
16:34
Periodicals
Blackstone discussed with Citadel about buying stake, WSJ reports »

Blackstone has held talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

16:29
10/13/19
10/13
16:29
10/13/19
16:29
Periodicals
Google bars high-interest consumer loan services from app store, WSJ reports »

Google has barred…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

16:28
10/13/19
10/13
16:28
10/13/19
16:28
General news
Trump working with Congress on 'powerful' Turkey sanctions »

President Trump tweeted…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$296.34

3.1 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$169.06

1.255 (0.75%)

16:23
10/13/19
10/13
16:23
10/13/19
16:23
Hot Stocks
Allergan, Molecular Partners present data from Phase 3 Abicipar pegol studies »

Allergan and Molecular…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$39.49

1.8 (4.78%)

, UBER

Uber

$30.09

1.19 (4.12%)

16:04
10/13/19
10/13
16:04
10/13/19
16:04
Periodicals
Lyft sues NYC over cruising time caps, Reuters reports »

Following its rival…

LYFT

Lyft

$39.49

1.8 (4.78%)

UBER

Uber

$30.09

1.19 (4.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 04

    Nov

  • 07

    Nov

  • 19

    Nov

GM

General Motors

$35.57

0.9 (2.60%)

15:59
10/13/19
10/13
15:59
10/13/19
15:59
Periodicals
UAW boosting strike pay as General Motor walkout continues, Reuters says »

The United Auto Workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MRK

Merck

$84.31

0.6 (0.72%)

, JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

15:49
10/13/19
10/13
15:49
10/13/19
15:49
Periodicals
Congo to start using Johnson & Johnson Ebola vaccine next month, Reuters says »

Health authorities in…

MRK

Merck

$84.31

0.6 (0.72%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

HMTV

Hemisphere Media

$11.70

0.05 (0.43%)

15:48
10/13/19
10/13
15:48
10/13/19
15:48
Initiation
Hemisphere Media initiated  »

Hemisphere Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.11

0.31 (0.87%)

15:37
10/13/19
10/13
15:37
10/13/19
15:37
Hot Stocks
Pfizer presents Phase 3 data for Abrocitinib in moderate to severe AD »

Pfizer announced complete…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

CNCE

Concert Pharmaceuticals

$5.85

(0.00%)

15:29
10/13/19
10/13
15:29
10/13/19
15:29
Hot Stocks
Concert Pharmaceuticals presents Phase 2 data in Alopecia Areata »

Concert Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$76.14

0.38 (0.50%)

15:23
10/13/19
10/13
15:23
10/13/19
15:23
Hot Stocks
Incyte announces 52-week results from Phase 2 study of Ruxolitinib cream »

Incyte announced 52-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

LLY

Eli Lilly

$108.37

1.54 (1.44%)

14:15
10/13/19
10/13
14:15
10/13/19
14:15
Hot Stocks
Eli Lilly says Taltz met co-primary endpoints in Phase 3 plaque psoriasis study »

Eli Lilly announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

PCG

PG&E

$8.08

0.3 (3.86%)

07:46
10/13/19
10/13
07:46
10/13/19
07:46
Hot Stocks
PG&E says all customers impacted by safety shutoffs now have power »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 07

    Jan

BNTX

BioNTech

$13.50

-0.85 (-5.92%)

, VIR

Vir Biotechnology

$14.06

(0.00%)

07:18
10/13/19
10/13
07:18
10/13/19
07:18
On The Fly
Opening Day: BioNTech raises $150M in smaller than expected IPO »

BioNTech (BNTX) raised…

BNTX

BioNTech

$13.50

-0.85 (-5.92%)

VIR

Vir Biotechnology

$14.06

(0.00%)

HBT

HBT Financial

$15.56

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

SFTBY

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

KRAT

Karat Packaging

$0.00

(0.00%)

POST

Post Holdings

$101.19

1.94 (1.95%)

IPHA

Innate Pharma

$0.00

(0.00%)

BRBR

BellRing Brands

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 17

    Oct

  • 17

    Oct

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

, BAYRY

Bayer

$0.00

(0.00%)

04:55
10/13/19
10/13
04:55
10/13/19
04:55
Conference/Events
Healthcare Made Practical to hold a symposium »

Symposium on Clinical…

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

BAYRY

Bayer

$0.00

(0.00%)

BSX

Boston Scientific

$38.22

0.22 (0.58%)

BTG

B2Gold

$3.25

-0.2 (-5.80%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

LLY

Eli Lilly

$108.37

1.54 (1.44%)

MDT

Medtronic

$107.61

0.24 (0.22%)

PFE

Pfizer

$36.11

0.31 (0.87%)

PHG

Philips

$42.88

0.99 (2.36%)

TRUMY

Terumo

$0.00

(0.00%)

VAR

Varian Medical

$110.78

1.84 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 13

    Nov

AMBA

Ambarella

$53.62

1.25 (2.39%)

, ON

ON Semiconductor

$18.74

0.67 (3.71%)

09:31
10/12/19
10/12
09:31
10/12/19
09:31
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AMBA

Ambarella

$53.62

1.25 (2.39%)

ON

ON Semiconductor

$18.74

0.67 (3.71%)

AAPL

Apple

$236.21

6.12 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 28

    Oct

  • 30

    Oct

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

, AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

08:48
10/12/19
10/12
08:48
10/12/19
08:48
Periodicals
Bed Bath & Beyond not a bargain, Barron's says »

While Bed Bath &…

BBBY

Bed Bath & Beyond

$12.98

0.89 (7.36%)

AMZN

Amazon.com

$1,730.79

11.115 (0.65%)

TGT

Target

$111.86

1.29 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

SNE

Sony

$58.16

0.83 (1.45%)

, MSFT

Microsoft

$139.62

0.52 (0.37%)

08:39
10/12/19
10/12
08:39
10/12/19
08:39
Periodicals
Activision, Take-Two to benefit from next videogame cycle, Barron's says »

Sony (SNE) has announced…

SNE

Sony

$58.16

0.83 (1.45%)

MSFT

Microsoft

$139.62

0.52 (0.37%)

ATVI

Activision Blizzard

$54.80

1.1 (2.05%)

TTWO

Take-Two

$122.42

0.02 (0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 21

    Nov

  • 21

    Nov

K

Kellogg

$62.14

-0.27 (-0.43%)

08:27
10/12/19
10/12
08:27
10/12/19
08:27
Periodicals
Kellogg stock looking like worth 'snacking on,' Barron's says »

Kellogg's stock fell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

, ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

08:20
10/12/19
10/12
08:20
10/12/19
08:20
Periodicals
J&J, Pentair among stocks with sage, growing dividends, Barron's says »

Investors seeking yield…

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

ITW

Illinois Tool Works

$154.56

4.68 (3.12%)

NUE

Nucor

$52.69

2.48 (4.94%)

PNR

Pentair

$37.33

1.215 (3.36%)

GWW

Grainger

$305.24

16.49 (5.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

, BAYRY

Bayer

$0.00

(0.00%)

04:55
10/12/19
10/12
04:55
10/12/19
04:55
Conference/Events
Healthcare Made Practical to hold a symposium »

Symposium on Clinical…

ANGO

AngioDynamics

$14.54

0.12 (0.83%)

BAYRY

Bayer

$0.00

(0.00%)

BSX

Boston Scientific

$38.22

0.22 (0.58%)

BTG

B2Gold

$3.25

-0.2 (-5.80%)

JNJ

Johnson & Johnson

$131.35

2.32 (1.80%)

LLY

Eli Lilly

$108.37

1.54 (1.44%)

MDT

Medtronic

$107.61

0.24 (0.22%)

PFE

Pfizer

$36.11

0.31 (0.87%)

PHG

Philips

$42.88

0.99 (2.36%)

TRUMY

Terumo

$0.00

(0.00%)

VAR

Varian Medical

$110.78

1.84 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 06

    Nov

  • 06

    Nov

  • 13

    Nov

THTX

Theratechnologies

$3.76

0.01 (0.27%)

18:32
10/11/19
10/11
18:32
10/11/19
18:32
Hot Stocks
Theratechnologies: Tesamorelin study results on NAFLD published in Lancet HIV »

Theratechnologies is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$20.76

0.76 (3.80%)

18:26
10/11/19
10/11
18:26
10/11/19
18:26
Hot Stocks
Wendy's CEO: We are really focused on the long term »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

  • 13

    Nov

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

, GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

18:25
10/11/19
10/11
18:25
10/11/19
18:25
Periodicals
Breaking Periodicals news story on Alphabet, Alphabet Class A »

DOJ to more closely…

GOOG

Alphabet

$1,213.86

5.88 (0.49%)

GOOGL

Alphabet Class A

$1,214.62

6.18 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

BA

Boeing

$374.90

3.97 (1.07%)

18:22
10/11/19
10/11
18:22
10/11/19
18:22
Hot Stocks
Boeing board separates CEO and Chairman roles »

Boeing announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.